C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024.
馬薩諸塞州沃特敦，2024年4月9日（環球新聞專線）——致力於推進靶向蛋白質降解科學的臨床階段生物製藥公司C4 Therapeutics, Inc.（C4T）（納斯達克股票代碼：CCC）今天宣佈，C4T管理層將參加2024年4月16日至4月17日虛擬舉行的Stifel 2024靶向腫瘤論壇的爐邊談話。
Fireside Chat Details:
Event: Stifel 2024 Targeted Oncology Forum
Date/Time: Tuesday, April 16, 2024 from 10:30 am ET – 10:55 am ET
爐邊聊天詳情：
活動：Stifel 2024 靶向腫瘤學論壇
日期/時間：美國東部時間 2024 年 4 月 16 日星期二上午 10:30 — 美國東部時間上午 10:55
A live webcast will be available on the Investors section of the company's website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 30 days following the live event.
公司網站的 “投資者” 部分將提供網絡直播，網址爲 www.c4therapeutics。網絡直播的存檔重播將在直播結束後的大約30天內提供。
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
關於 C4 療法
C4 Therapeutics（C4T）（納斯達克股票代碼：CCCC）是一家臨床階段的生物製藥公司，致力於兌現靶向蛋白質降解科學的承諾，創造改變患者生活的新一代藥物。C4T正在通過臨床研究和利用其TORPEDO推進靶向腫瘤學項目 該平台可高效設計和優化小分子藥物，以解決難以治療的疾病。C4T的降解劑藥物旨在利用人體的天然蛋白質回收系統快速降解致病蛋白，從而有可能克服耐藥性、不可藥物靶標和改善患者預後。欲了解更多信息，請訪問 www.c4therapeutics。
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
聯繫人：
投資者：
考特尼·索爾伯格
投資者關係高級經理
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
媒體：
Loraine Spreen
企業傳播與患者宣傳高級董事
LSpreen@c4therapeutics.com
譯文內容由第三人軟體翻譯。